Repligen (RGEN) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Repligen Corp  (NASDAQ: RGEN)

Repligen's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Repligen in the second quarter 2026?
Repligen Corp achieved a return on average equity (ROE) of 1.98 % in its second quarter 2026, which is below Repligen's average return on equity, which stands at 6.43%.

ROE decreased relative to the period ending , due to the decline in net income.

Within the Biotechnology & Pharmaceuticals industry 17 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 2134 to 2182.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change 2.44 % 6.04 % 6.76 % 3.29 % -
Y / Y Net Income Change -66.31 % 42.93 % - - 160.21 %
Net Income (TTM) in Millions 42 51 49 2 -14
Return On Equity (TTM) 1.98 % 2.46 % 2.37 % 0.09 % -0.69 %
RGEN's Total Ranking # 2182 # 2134 # 1899 # 1724 # 2054
Equity (TTM) in Millions 2,112 2,105 2,106 2,083 2,062
Seq. Equity Change 0.31 % -0.03 % 1.11 % 1.04 % 3.84 %
Seq. Net Income Change -39.9 % -37.28 % -10.89 % 0.3 % 154.99 %

Back to RGEN Management Effectiveness >> RGEN's 5 Years Annual ROE >> Compare RGEN ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 18
Sector # 181
Overall # 2182

Return On Equity Statistics
High Average Low
22.62 %
6.43 %
-1.29 %
(Sep 30 2013)  





RGEN Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 2,106 1,973 1,965 1,911 1,750
Y / Y Equity Change 6.76 % 0.4 % 2.83 % 9.18 % 14.45 %
Net Income in Millions 49 -26 36 186 128
Y / Y Net Income Change - - -80.86 % 44.95 % 114.08 %
Return On Equity 2.32 % -1.29 % 1.81 % 9.73 % 7.33 %

Back to RGEN Management Effectiveness >> RGEN's 5 Years Annual ROE >> Compare RGEN ROE to its Competitors




Annual Roe Comment
In 2025 ROE improved to 2.32 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
RGEN's' Return on Equity at Yahoo Finance
RGEN's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for RGEN's Competitors
Subscribers only: Roe for Repligen's Suppliers
Subscribers only: Return On Equity for RGEN's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE
Pfizer Inc  4.91 %
Privia Health Group Inc   4.23 %
Becton Dickinson And Company  3.79 %
Alkermes Plc   3.72 %
Lifemd Inc   3.47 %
Lifestance Health Group Inc   3.39 %
Revvity Inc  3.27 %
Bio rad Laboratories Inc   3.15 %
Envista Holdings Corporation  3.08 %
Immucell Corporation  2.68 %
Surgery Partners Inc   2.63 %
Mimedx Group Inc   2.61 %
Cormedix Inc   2.18 %
Atricure Inc   2.14 %
Pacira Biosciences inc   2.13 %
Warby Parker Inc   2.06 %
Repligen Corp  1.98 %
Arvinas Inc   1.91 %
Waters Corporation  1.88 %
Omada Health Inc   1.84 %
Radnet Inc   1.42 %
Icu Medical Inc  1.41 %
Biomarin Pharmaceutical Inc  1.18 %
Staar Surgical Co  1.08 %
Champions Oncology Inc   0.94 %
Delcath Systems Inc   0.46 %

Date modified: 2026-09-26T07:09:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.